GURUFOCUS.COM » STOCK LIST » Industrials » Industrial Products » Solvonis Therapeutics PLC (LSE:SVNS) » Definitions » Future Policy Benefits

Solvonis Therapeutics (LSE:SVNS) Future Policy Benefits


View and export this data going back to 2022. Start your Free Trial

What is Solvonis Therapeutics Future Policy Benefits?

Future Policy Benefits only applies to insurance companies.


Solvonis Therapeutics Business Description

Traded in Other Exchanges
N/A
Address
Eccleston Yards, 25 Eccleston Place, London, GBR, SW1W 9NF
Graft Polymer (UK) PLC focuses on the development of polymer modification and drug delivery systems. It has licensed its Drug Delivery System platform IP to MGC Pharmaceuticals in relation to MGC Pharma's CimetrA product. The group's products address customer needs across a wide range of end-use markets, from automotive through to medical, and are not dependent on one market segment. The Company operates in two business segments being polymer development and production in Slovenia.